| About the author: |
V. H. Psarova, M. M. Kochuieva, I. I. Hrek, I. V. Gogunska, O. L. Yakovenko, O. S. Komissarova, T. V. Svyatenko |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The article focuses on studying the genetic determinants affecting the development of pseudoresistant arterial hypertension in patients with accompanying obesity. We examined 200 stage II hypertensive patients with class I–II obesity aged 45–55. Treatment is provided following the 2018 European guidelines. If the target level of blood pressure after three months of dual antihypertensive therapy with perindopril and amlodipine was not reached, the thiazide-like diuretic indapamide was additionally prescribed. Diet therapy aimed at lowering blood pressure to target values and correcting body weight was prescribed as a non-drug treatment. Patients were advised to increase physical activity by fast walking for at least 45 minutes daily. Resistant hypertension was diagnosed in 48 patients, while pseudoresistance was detected in 27 patients. It was established that the determinants of pseudoresistant hypertension in patients with concomitant obesity are the genetic polymorphism of IRS-1 and ADIPOQ, relative wall thickness of the left ventricular, HOMA index, body mass index and mean blood pressure. Concurrently, the main predictors are IRS-1 and ADIPOQ polymorphisms. |
| Tags |
genetic polymorphism,arterial hypertension,obesity,resistant hypertension,antihypertensive therapy,logistic regression |
| Bibliography |
- Mishchenko LA, Kupchynska OH, Matova OO, Serbeniuk KI, Hulkevych OV, Radchenko VV. Osoblyvosti urazhennia orhaniv-misheney u patsiientiv iz rezystentnoyu arterialnoyu hipertenziyeyu. Arterialna hipertenziya. 2020;13(2–3):66–74. doi:10.22141/2224-1485.13.2-3.2020.205339. [in Ukrainian]
- Radchenko HD, Rekovets OL, Sirenko YuM. Prohnoz ta chynnyky ryzyku nespryiatlyvoho perebihu zakhvoriuvannia u khvorykh z arterialnoyu hipertenziyeyu ta z yiyi rezystentnoyu formoyu. Ukrainskyi terapevtychnyi zhurnal. 2023;1:13–21. doi:10.30978/UTJ2023-1-13. [in Ukrainian]
- Tseluyko VI. Realii lecheniya arterialnoy gipertenzii v Ukraine: rezultaty kogortnogo issledovaniya SISTEMA-2. Ukr Kardiolog Zh. 2018;25(1):13–20. [in Russian]
- Abdellaoui A, Yengo L, Verweiy KJ, Visscher PM. 15 years of GWAS discovery: Realizing the promise. AJHG. 2023 Feb;110:179–194. doi:10.1016/j.ajhg.2022.12.011.
- Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. J. Circ. Res. 2019 Mar 29;124(7):1061–1070. doi:10.1161/CIRCRESAHA.118.312156.
- De Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018 Jan;84(1):18–24. doi:10.1111/bcp.13402.
- Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High‐risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. J. Hypertens. 2018;36:1427–1440. doi:10.1097/HJH.0000000000001730.
- Muxfeldt ES, Chedier B, Rodrigues CIS. Resistant and refractory hypertension: two sides of the same disease? J. Bras. Nefrol. 2019 Apr – Jun;41(2):266–274. doi:10.1590/2175-8239-jbn-2018-0108.
- Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients Heart 2019 Jan;105:98–105. doi:10.1136/heartjnl-2018-313599.
- Ramzy DI. Definition of hypertension and pressure goals during treatment (ESC-ESH Guidelines 2018). E-Journal of Cardiology Practice. 2019 Aug;17. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-17/definition-of-hypertension-and-pressure-goals-during treatment-esc-esh-guidelin.
- Ribeiro F, Teixeira M, Alves AJ, Sherwood A, Blumenthal JA. Lifestyle Medicine as a Treatment for Resistant Hypertension. Curr Hypertens Rep. 2023 Jul 20. doi:10.1007/s11906-023-01253-5
- Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. J. Gland. Surg.2020 Feb;9(1):80–93. doi:10.21037/gs.2019.12.03.
- Whelton PK, Carey RM, Aronow WS, Casey DEJr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Hypertension. 2018 Jun;71(6):1269–1324. doi:10.1161/HYP.0000000000000066.
- Wijkman MO, Malachias MVB, Claggett BL, Cheng S, Matsushita K, Shah AM, et al. Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. J Clin Hypertens (Greenwich). 2021 Oct;23(10):1887–1896. doi:10.1111/jch.14269.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953–2041. doi: 10.1097/HJH.0000000000001940.
|
| Publication of the article |
«World of Medicine and Biology» №3(85), 2023 year, 162-166 pages, index UDK 616.12-008.331.1+613.25+575]-07-085 |
| DOI |
10.26724/2079-8334-2023-3-85-162-166 |
